Gland Pharma Limited

NSEI:GLAND Stock Report

Market Cap: ₹292.0b

Gland Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Srinivas Sadu

Chief executive officer

₹70.2m

Total compensation

CEO salary percentage95.3%
CEO tenure5.7yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3.9yrs

Recent management updates

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Nov 07
Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Oct 26
Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Oct 01
Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Sep 05
Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 09
Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22
Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25
Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19
Is Gland Pharma (NSE:GLAND) A Risky Investment?

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16
Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20
Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07
Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22
Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14
Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Feb 08
Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

CEO Compensation Analysis

How has Srinivas Sadu's remuneration changed compared to Gland Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹7b

Jun 30 2024n/an/a

₹7b

Mar 31 2024₹70m₹67m

₹8b

Dec 31 2023n/an/a

₹7b

Sep 30 2023n/an/a

₹7b

Jun 30 2023n/an/a

₹7b

Mar 31 2023₹124m₹61m

₹8b

Dec 31 2022n/an/a

₹10b

Sep 30 2022n/an/a

₹10b

Jun 30 2022n/an/a

₹11b

Mar 31 2022₹124m₹61m

₹12b

Dec 31 2021n/an/a

₹12b

Sep 30 2021n/an/a

₹11b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹89m₹31m

₹10b

Dec 31 2020n/an/a

₹9b

Jun 30 2020n/an/a

₹9b

Mar 31 2020₹59m₹32m

₹8b

Mar 31 2019₹23mn/a

₹5b

Mar 31 2018₹11m₹5m

₹3b

Compensation vs Market: Srinivas's total compensation ($USD825.67K) is above average for companies of similar size in the Indian market ($USD589.68K).

Compensation vs Earnings: Srinivas's compensation has been consistent with company performance over the past year.

CEO

Srinivas Sadu (55 yo)

5.7yrs

Tenure

₹70,150,000

Compensation

Mr. Srinivas Sadu, B. Pharm, M. S., MBA has been Executive Director and Chief Executive Officer at Gland Pharma Ltd. since April 25, 2019 and serves as its Executive Chairman from June 10, 2024. He had bee...

Leadership Team

NamePositionTenureCompensationOwnership
Srinivas Sadu
CEO & Executive Chairman5.7yrs₹70.15mno data
Ravi Mitra
Chief Financial Officer5.3yrs₹20.45mno data
Sampath Pallerlamudi
Company Secretary & Vice-President of Compliance & CSRno data₹6.05mno data
Satnam Loomba
Chief Operating Officerless than a yearno datano data
Ankit Gupta
Head of Investments1.3yrsno datano data
Surinder Koul
Head of Domestic Marketingless than a yearno datano data
K Rao
Head of Qualityless than a yearno data0.0012%
₹ 3.6m
R.V.R. Sastry
Senior Vice President of R&Dless than a yearno datano data
Rong Wu
Chief Financial Controllerno datano data0.000020%
₹ 58.4k

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: GLAND's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Srinivas Sadu
CEO & Executive Chairman5.7yrs₹70.15mno data
Naina Lal Kidwai
Independent Director3.6yrs₹10.50mno data
Udo Vetter
Independent Director6.8yrs₹3.00mno data
Essaji Vahanvati
Independent Director4.3yrs₹3.00mno data
Wenjie Zhang
Non-Executive and Non-Independent Directorless than a yearno datano data
Jia Ai Zhang
Non-Independent Non Executive Director3.6yrsno datano data
Satyanarayana Chavali
Independent Director6.1yrs₹3.00mno data
Wei Huang
Non-Executive Non-Independent Directorno datano datano data

3.9yrs

Average Tenure

60yo

Average Age

Experienced Board: GLAND's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gland Pharma Limited is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Neha ManpuriaBofA Global Research
Vivek AgrawalCitigroup Inc